See the DrugPatentWatch profile for semaglutide

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a medication used to treat type 2 diabetes and, in some cases, obesity. It is commercially available under the brand names Ozempic and Rybelsus for diabetes indications and as Wegovy for obesity management. The patent expiration date for semaglutide is a topic of interest for those in the pharmaceutical industry, healthcare providers, and patients.

According to DrugPatentWatch.com, the basic patent for semaglutide expired in the United States on December 27, 2021 [1]. However, it is essential to note that additional patents may still be in force, providing exclusivity for specific formulations or methods of administration. For instance, Novo Nordisk, the company that developed and markets semaglutide, has several patents related to the drug's use and formulation that extend its market exclusivity beyond the basic compound patent expiration [2].

In summary, while the basic patent for semaglutide has expired, other patents may still protect specific formulations or applications of the drug. This means that generic versions of semaglutide may not become available immediately.

Sources:

1. DrugPatentWatch.com. (n.d.). Semaglutide. Retrieved from https://www.drugpatentwatch.com/drugs/semaglutide
2. Novo Nordisk. (2021). Patent Expiry Dates for Novo Nordisk Products. Retrieved from https://www.novonordisk.com/content/dam/Denmark/HQ/www-novonordisk-com/Investors/Documents/Patent-expiry-dates-for-Novo-Nordisk-products.pdf